Skip to main content

Table 1 Challenges and solutions for difficult SABR scenarios

From: A critical review of recent developments in radiotherapy for non-small cell lung cancer

Clinical scenario Challenges Potential solutions being explored
Pre Treatment Incorporating patient preferences for treatment Choice of SABR in operable NSCLC • Shared decision-making [19, 20]
• Comparative effectiveness research (including patient-reported outcomes, QOL and cost-effectiveness analyses) with “big data” strategies to facilitate data mining
• RCTs underway (NCT02629458, NCT01753414, NCT02468024, VALOR study)
Obtaining a diagnosis Risks of treating benign disease Risks of biopsy in frail patients •Use validated models for cancer risk determination in a given population [9]
• Explore blood biomarkers [123]
Treatment Central tumors
Multiple primary lung cancers
Proximity to OARs
Uncertainty in OAR location
Uncertainly in OAR dose constraints
• “Big data” strategies to establish more reliable OAR dose constraints
• MRI-guided adaptive RT [44]
• Protons [41]
Oligometastases Higher pneumonitis risk
Identify molecular and clinical characteristics of patients likely to benefit from ablative local therapies
Optimize sequencing of RT and new systemic treatments
• Phase I-II trials, as well as randomized trials
Follow-up Detection of recurrences Distinguishing post-RT fibrosis vs recurrent disease • Radiomic approaches [24]
Survivorship issues Loco-regional recurrences and second lung tumors
Smoking cessation
• Survivorship clinics [124]
• Patient-reported outcomes, including financial impact of treatments
  1. Abbreviations QOL quality of life, RT radiotherapy, SABR stereotactic ablative radiotherapy, NSCLC non-small cell lung cancer, OAR organ at risk, PTV planning target volume